Voyager Therapeutics, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Voyager Therapeutics, Inc
Deals In Depth: January 2023
Eight $1bn+ alliances were penned in January. Topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Al Sandrock On His First Mission At Voyager: Cracking The Tau Alzheimer’s Puzzle
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Third Rock Ventures, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.